Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Attention deficit hyperactivity disorder therapy update: extended-release methylphenidate].

F Mulas1, L Mattos, S Hernández-Muela

  • 1Hospital Infantil La Fe, 46009 Valencia, Espana. fernando.mulas@invanep.es

Revista De Neurologia
|March 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for inactivation of seafood Anisakis larvae and prevention of human anisakiasis: a mini-review.

European review for medical and pharmacological sciences·2023
Same author

[Twenty years of neurodevelopment].

Revista de neurologia·2018
Same author

[Randomised controlled study of inter-hemispheric electroencephalographic coherence following assisted therapy with dolphins in children with autism spectrum disorders].

Revista de neurologia·2018
Same author

[Concordances between autism spectrum disorders and attention deficit hyperactivity disorder].

Revista de neurologia·2018
Same author

[A study of primary school teachers' knowledge of attention deficit hyperactivity disorder].

Revista de neurologia·2018
Same author

Mutual information-based feature selection for low-cost BCIs based on motor imagery.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2017

Extended-release methylphenidate (MPT) improved symptom control and compliance in children with ADHD compared to immediate-release MPT. This formulation offers greater satisfaction for families managing ADHD symptoms.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pediatrics

Context:

  • Attention deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder in pediatric practice.
  • Methylphenidate (MPT) is the most common pharmacological treatment for ADHD.
  • Understanding MPT formulations is crucial for effective ADHD management.

Purpose:

  • To compare the efficacy and patient satisfaction of extended-release MPT (OROS technique) versus immediate-release MPT in pediatric ADHD patients.
  • To evaluate compliance, safety, and symptom control with different MPT formulations.
  • To determine the preferable MPT formulation for managing ADHD in children and adolescents.

Summary:

  • A study involving 93 pediatric patients (6-18 years) compared immediate-release MPT with extended-release MPT (OROS).

Related Experiment Videos

  • Patients transitioned to extended-release MPT were assessed for compliance, effectiveness, safety, family preference, and afternoon symptom control.
  • Extended-release MPT demonstrated improved compliance and greater satisfaction in controlling afternoon ADHD symptoms.

    • Impact:

    • The findings suggest extended-release MPT (OROS) offers significant advantages in ADHD management, particularly for symptom control and patient/family adherence.
    • This research provides valuable insights for clinicians selecting MPT formulations for pediatric ADHD.
    • Optimizing MPT delivery can enhance treatment outcomes and quality of life for children with ADHD.